All In Biotech

Drug Trial Radar · NCT03684044

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

Last checked: Nov 20, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

363

Actual

Start

Jan 8, 2019

Primary completion

Mar 16, 2020

Study completion Mar 16, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.

Conditions

  • Influenza

Interventions

  • Baloxavir MarboxilDrug

    Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.

  • PlaceboOther

    Participants will receive matching placebo on Days 1, 4 and 7.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical ImprovementTime frame: Up to Day 35

Locations

170 sites in 28 countries. Site status is shown where the registry gives one.

  • Torrance Memorial Medical Center

    Torrance, California

  • Denver Health Medical Center

    Denver, Colorado

  • Atlanta Institute For Medical Research, Inc; DeKalb Medical Pharmacy

    Decatur, Georgia

  • University of Chicago; Oncology Dept

    Chicago, Illinois

  • NorthShore University HealthSystem

    Evanston, Illinois

  • Barnum Medical Research, Inc.

    Natchitoches, Louisiana

  • Detroit Receiving Hospital

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Mercury Street Medical Group

    Butte, Montana

  • Creighton University Medical Center

    Omaha, Nebraska

  • New York-Presbyterian Brooklyn Methodist Hospital; Department of Emergency Medicine

    Brooklyn, New York

  • Temple University Hospital ; Lung Center

    Philadelphia, Pennsylvania

  • Salem Veterans Affairs Medical Center - NAVREF; Pharmacy

    Salem, Virginia

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Instituto Medico Platense

    La Plata, Argentina

  • Royal Brisbane & Womens Hospital; Pharmacy Department

    Herston, Queensland, Australia

  • Royal Children's Hospital Melbourne - PIN

    Parkville, Victoria, Australia

  • Hopital Erasme; Chest Medicine, Cardiac & Thoracic Surgery

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc; Hematology

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Santa Casa de Misericordia; de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital Sao Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Centro de Estudos Clinicos do Interior Paulista

    Jaú, São Paulo, Brazil

  • Multiprofile Hospital For Active Treatment Sveta Ekaterina Dimitrovgrad EOOD; Internal Diseases

    Dimitrovgrad, Bulgaria

  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD

    Haskovo, Bulgaria

  • MHAT Stamen Iliev AD; Pharmacy

    Montana, Bulgaria

  • University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD; Pharmacy

    Plovdiv, Bulgaria

  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Dr. D. Gramatikov - Ruse

    Rousse, Bulgaria

  • Multiprofile Hospital for Active Treatment - Samokov EOOD

    Samokov, Bulgaria

  • Multiprofile Hospital For Active Treatment Sliven То Military Hospital Sofia; Pharmacy

    Sliven, Bulgaria

  • Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD; Pharmacy

    Smolyan, Bulgaria

  • First Multiprofile Hospital for Active Treatment - Sofia EAD

    Sofia, Bulgaria

  • Fifth Multiprofile Hospital for Active Treatment - Sofia EAD; Pharmacy

    Sofia, Bulgaria

  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia; Pharmacy

    Sofia, Bulgaria

  • National Multiprofile Transport Hospital Tzar Boris Ill; Clinic of Internal Diseases

    Sofia, Bulgaria

  • Multiprofile District Hospital for Active Treatment Dr. Stefan Cherkezov AD; Pharmacy

    Veliko Tarnovo, Bulgaria

  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa; Pharmacy

    Vratsa, Bulgaria

  • Institut Universitaire de Cardiologie et de Pneumologie

    Québec, Canada

  • Peter Lougheed Centre

    Calgary, Alberta, Canada

  • Foothills Medical Centre

    Calgary, Alberta, Canada

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.